Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02128412
Other study ID # 2013/167
Secondary ID
Status Active, not recruiting
Phase N/A
First received April 28, 2014
Last updated October 14, 2016
Start date February 2014
Est. completion date November 2016

Study information

Verified date October 2016
Source Sydney South West Area Health Service
Contact n/a
Is FDA regulated No
Health authority Australia: Human Research Ethics Committee
Study type Interventional

Clinical Trial Summary

Stent placement is now widely accepted to improve the results of angioplasty (an operation to widen the blood vessel) and decreasing the need for further surgery. Despite their worldwide acceptance, stent usage is still limited by renarrowing which occurs within the stent (restenosis) in some patients within the first six months. In addition there still exists a small risk of heart attacks soon after the stent is placed.

The purpose of this study is to test the safety and tolerability of trying to place the stents using a different strategy of using low pressure oversized balloon inflations as opposed to the usual high pressure balloon inflations. This may reduce injury to the artery and reduce the chance of renarrowing of the stent. In order to ensure this is a safe and effective way of performing the procedure the investigators intend to use an Intravascular ultrasound (IVUS) catheter to look from inside the artery at the stents. IVUS has proven to be the best way of ensuring optimal stent placement.

Primary hypothesis: Stents will be equally well expanded and apposed using a strategy of oversized stenting at normal inflation pressures ( < 10 atmospheres ) as compared to high pressure inflation (≥14 atmospheres) as guided by intravascular ultrasound imaging.

Secondary Hypothesis: There will be no difference in acute clinical endpoints (death, myocardial infarction, urgent revascularisation or stent thrombosis) using a strategy of oversized stenting at normal inflation pressure as compared to high pressure inflation.

Tertiary Hypothesis: If the above is shown to be true the investigators would hope to expand the study in order to reveal a decrease in stent restenosis using a strategy of lower pressure balloon inflations. The investigators will assess the deployment characteristics of drug eluting versus bare metal stents


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 40
Est. completion date November 2016
Est. primary completion date October 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria:

- Patients who are scheduled for a coronary angioplasty and stenting

- Single de novo artery stenosis are eligible for this study

- Target lesion needs to be less than 30mm long and located in a vessel more than 2.5 mm in diameter

Exclusion Criteria:

- Contraindication to antiplatelet therapy;

- Ostial lesion;

- Excessive vessel tortuosity;

- Lesion at a significant bifurcation (subbranch = 2mm in diameter);

- Suspected intracoronary thrombus.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
Oversized stent deployed at low pressure (Multi-Link Bare Metal Stent or Xience Prime Evenolimus Eluting Stent)
Stent can include both bare metal stents and drug eluting stents. Depending on availabilities, different stent brands may be used.
Stent deployed at high pressure (Multi-Link Bare Metal Stent or Xience Prime Evenolimus Eluting Stent)
Stent can include both bare metal stents and drug eluting stents. Depending on availabilities, different stent brands may be used.

Locations

Country Name City State
Australia Department of Cardiology Liverpool New South Wales

Sponsors (1)

Lead Sponsor Collaborator
Sydney South West Area Health Service

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of stents which are optimally deployed as assessed against the MUSIC criteria The criteria for optimal stent expansion are:
1. Complete apposition of the stent over its entire length against the vessel wall.
2a. In stent minimal luminal area (MLA) >= 90% of the average reference luminal area or >=100% of lumen area of the reference segment with the lowest lumen area.
In stent lumen area of proximal stent entrance >= 90% of proximal lumen area. 2b. Where the instent luminal area is in excess of 9.0 mm2 , the following criteria apply: In stent MLA > 80% of the average reference lumen area or >=90% of lumen area of the reference segment with the lowest lumen area.
In stent lumen area of proximal stent entrance >= 90% of proximal lumen area. 3. Symmetric stent expansion defined by lumen diameter (LD)min / LD max >= 0.7
A less rigorous criteria for stent expansion will also be assessed:
In stent MLA > 80% of the average reference lumen area; &
Complete apposition of the stent over its entire length against the vessel wall
Immediately after stent is deployed until optimal deployment is achieved Yes
Secondary Clinical endpoints including death, myocardial infarction, coronary artery bypass surgery, repeat percutaneous intervention, stent thrombosis, myonecrosis 1-3 days following procedure and at 6 months No